Nasdaq
$0.1296▼ 2.78%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.8MShares out 13.9M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
29- 3d agoAfter-hours26.10.22 05:15PRER14AOther#●●●#●●●#●●●
Vivos Therapeutics, Inc.
Vivos Therapeutics will hold its 2026 Annual Meeting on December 2, 2026, to vote on 10 proposals, including a reverse stock split at a ratio of 1-for-20 to 1-for-40 and a conversion to a Nevada corporation. The meeting will also address the approval of common stock issuances related to convertible preferred stock and warrants, as well as an increase of 4.9 million shares authorized under the 2024 Omnibus Equity Incentive Plan.…more
$0.1296-2.78%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 4d agoPre-market26.10.21 20:008-KKey event
Vivos Therapeutics, Inc.
Vivos Therapeutics has regained compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million. This was achieved following the issuance of $12 million in Series C Convertible Preferred Stock as part of the SOD Sciences acquisition, which is expected to increase stockholders' equity by over $10 million. The company remains subject to potential delisting if it fails to demonstrate continued compliance in future periodic reports.…more
$0.1296-2.78%vs prev closeView filingShare - 5d agoAfter-hours26.10.20 05:58PRE 14AOther
Vivos Therapeutics, Inc.
Vivos Therapeutics will hold its 2026 Annual Meeting on November 18, 2026, to vote on 10 proposals, including a 1-for-20 to 1-for-40 reverse stock split and reincorporation from Delaware to Nevada. The company is also seeking shareholder approval to issue up to 18,476,959 shares upon the conversion of securities held by New Seneca Partners and up to 80,000,000 shares upon the conversion of Series C Preferred Stock.…more
$0.1296-2.78%vs prev closeView filingShare
28 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoPre-market26.10.21 20:04#●●●
Vivos Therapeutics Regains Nasdaq Compliance
Vivos Therapeutics has regained compliance with Nasdaq's stockholders' equity requirements. This development removes the risk of delisting and is expected to contribute to stock price stability.…more
$0.1296-2.78%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 5d agoAfter-hours26.10.20 06:01
●●●●●●●● ●●●●● ●●●●●●
Vivos Therapeutics has acquired a stake in SOD Sciences and diagnostic testing rights, aiming to meet Nasdaq's minimum stockholders' equity requirement. The deal relies on the issuance of preferred stock, and actual revenue growth remains subject to future definitive agreements and bankruptcy court approvals.…more
$0.1296-2.78%vs prev close - 10.15Pre-market26.10.15 21:45
●●●●●●●● ●●●●● ●●●●●●
Vivos Therapeutics is acquiring an equity stake in SOD Sciences and rights to a proprietary diagnostic test to expand its healthcare service offerings. While the deal aims to improve stockholders' equity for Nasdaq compliance, it involves the issuance of convertible preferred stock that could lead to future dilution.…more
$0.1296-2.78%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report